Find out more about Max Wolf's experience
Max Wolf's highlights
Max Wolf's selected work
Infrastructure Support For The Australasian Leukaemia And Lymphoma Group (Allg) Trial Cent..
Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia U..
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patien..
The utility and limitations of F-18-fluorodeoxyglucose positron emission tomography with c..
A multicentre retrospective comparison of central nervous system prophylaxis strategies am..
Displaying the most recent project by Max Wolf.
Displaying the 19 most recent scholarly works by Max Wolf.
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, David M Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony Mills, David Simpson, Constantine Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg
Journal article | 2019 | Leukemia & Lymphoma
The management of CML in pregnancy is challenging with the need to balance disease control against potential teratogenic effects o..
Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment
Thomas Lew, Mary Ann Anderson, Constantine S Tam, Sasanka Handunnetti, Dennis Carney, Max Wolf, Surender Juneja, David Alan Westerman, Andrew W Roberts, John F Seymour
Conference Proceedings | 2018 | Blood
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy
Thomas E Lew, Chan Y Cheah, Dennis A Carney, H Miles Prince, Max Wolf, Ali Bazargan, E Henry Januszewicz, Robin Filshie, David Westerman, John F Seymour, Constantine S Tam
Journal article | 2016 | Leukemia & Lymphoma
The utility and limitations of F-18-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
Chan Y Cheah, Michael S Hofman, John F Seymour, David S Ritchie, Michael Dickinson, Andrew Wirth, H Miles Prince, Max Wolf, Elchanan H Januszcewicz, Dennis A Carney, Kirsten E Herbert, Simon J Harrison, Kate L Burbury, Constantine S Tam
Journal article | 2015 | Leukemia & Lymphoma
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
CY Cheah, KE Herbert, K O'Rourke, GA Kennedy, A George, PL Fedele, M Gilbertson, SY Tan, DS Ritchie, SS Opat, HM Prince, M Dickinson, K Burbury, M Wolf, EH Januszewicz, CS Tam, DA Westerman, DA Carney, SJ Harrison, JF Seymour
Journal article | 2014 | British Journal of Cancer
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
Chan Y Cheah, Michael Dickinson, Michael S Hofman, Anupkumar George, David S Ritchie, H Miles Prince, David Westerman, Simon J Harrison, Kate Burbury, Max Wolf, Henry Januszewicz, Kirsten E Herbert, Dennis A Carney, Constantine Tam, John F Seymour
Journal article | 2014 | Annals of Hematology
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, K Burbury, M Wolf, H Januszewicz, K Herbert, HM Prince, DA Carney, DS Ritchie, RJ Hicks, JF Seymour
Journal article | 2013 | British Journal of Cancer
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Nicole Wong Doo, Philip A Thompson, H Miles Prince, John F Seymour, David Ritchie, Kerrie Stokes, Kate Burbury, Max Wolf, Trish Joyce, Simon J Harrison
Journal article | 2013 | Leukemia and Lymphoma
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
Andrew Wirth, Andrew Grigg, Max Wolf, David Goldstein, Carol Johnson, Sidney Davis, Gaelle Dutu, Poppy Kypreos, Carole Smith, Andrew Kneebone, Mark Herzberg, David Joseph, John Catalano, Daniel Roos, Janey Stone, John Reynolds
Journal article | 2011 | Leukemia and Lymphoma
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia
Stefan Peinert, Constantine S Tam, H Miles Prince, John Scarlett, Max M Wolf, E Henry Januszewicz, David Westerman, John F Seymour
Journal article | 2010 | Leukemia and Lymphoma
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma
Andrew P Grigg, Janey Stone, Alvin D Milner, Anthony P Schwarer, Max Wolf, H Miles Prince, John Seymour, Devinder Gill, David Ellis, John Bashford
Journal article | 2010 | Leukemia and Lymphoma
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator
KE Herbert, S Morgan, HM Prince, DA Westerman, MM Wolf, DA Carney, K Yuen, J di Iulio, JF Seymour
Journal article | 2009 | Leukemia
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders
Mark N Polizzotto, Constantine S Tam, Aivin Milner, E Henry Januszewicz, H Miles Prince, David Westerman, Max M Wolf, John F Seymour
Journal article | 2006 | Cancer
Medicine - St Vincent'S Hospital